NCT04647903View on ClinicalTrials.gov

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 17, 2021

Study Completion Date

December 17, 2021

Conditions
ADHDNarcolepsy
Interventions
DRUG

ADAIR 10 mg IR tablets

manipulated ADAIR 3x10mg

DRUG

d-amphetamine sulfate

crushed d-amphetamine sulfate 3x10mg

DRUG

Placebo

placebo for oral and intranasal administration

Trial Locations (1)

84124

Vallon Investigational Site, Salt Lake City

All Listed Sponsors
lead

Vallon Pharmaceuticals, Inc.

INDUSTRY

NCT04647903 - Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) | Biotech Hunter | Biotech Hunter